GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (NYSE:TEVA) » Definitions » PE Ratio

Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) PE Ratio

: At Loss (As of Today)
View and export this data going back to 1990. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-16), Teva Pharmaceutical Industries's share price is $13.09. Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47. Therefore, Teva Pharmaceutical Industries's PE Ratio for today is At Loss.


The historical rank and industry rank for Teva Pharmaceutical Industries's PE Ratio or its related term are showing as below:

TEVA' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: 26.5   Max: 3148.65
Current: At Loss


During the past 13 years, the highest PE Ratio of Teva Pharmaceutical Industries was 3148.65. The lowest was 0.00. And the median was 26.50.


TEVA's PE Ratio is ranked worse than
100% of 608 companies
in the Drug Manufacturers industry
Industry Median: 22.855 vs TEVA: At Loss

Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $0.41. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.

As of today (2024-04-16), Teva Pharmaceutical Industries's share price is $13.09. Teva Pharmaceutical Industries's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.56. Therefore, Teva Pharmaceutical Industries's PE Ratio without NRI for today is 5.11.

During the past 13 years, Teva Pharmaceutical Industries's highest PE Ratio without NRI was 13.33. The lowest was 1.34. And the median was 4.38.

Teva Pharmaceutical Industries's EPS without NRI for the three months ended in Dec. 2023 was $1.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $2.56.

During the past 12 months, Teva Pharmaceutical Industries's average EPS without NRI Growth Rate was 1.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -0.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was -9.50% per year.

During the past 13 years, Teva Pharmaceutical Industries's highest 3-Year average EPS without NRI Growth Rate was 76.90% per year. The lowest was -36.60% per year. And the median was 14.00% per year.

Teva Pharmaceutical Industries's EPS (Basic) for the three months ended in Dec. 2023 was $0.41. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.47.


Teva Pharmaceutical Industries PE Ratio Historical Data

The historical data trend for Teva Pharmaceutical Industries's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teva Pharmaceutical Industries Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 18.89 At Loss At Loss

Teva Pharmaceutical Industries Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teva Pharmaceutical Industries PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's PE Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's PE Ratio falls into.



Teva Pharmaceutical Industries PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Teva Pharmaceutical Industries's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=13.09/-0.470
=At Loss

Teva Pharmaceutical Industries's Share Price of today is $13.09.
Teva Pharmaceutical Industries's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.47.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Teva Pharmaceutical Industries  (NYSE:TEVA) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Teva Pharmaceutical Industries PE Ratio Related Terms

Thank you for viewing the detailed overview of Teva Pharmaceutical Industries's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Teva Pharmaceutical Industries (Teva Pharmaceutical Industries) Business Description

Address
124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
Executives
Dov Bergwerk officer: Acting Chief Legal Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Vikki L Conway officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Varda Shalev director MATAM PARK, BUILDING #5, HAIFA L3 3508409
Eliyahu Sharon Kalif officer: EVP, Chief Financial Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Amir Weiss officer: Chief Accounting Officer C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Angus Grant officer: EVP, Business Development C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric A Hughes officer: See "Remarks" C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Sven Dethlefs officer: EVP Global Marketing&Portfolio 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Eric Drape officer: Executive VP Global Operations C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
David Matthew Stark officer: Exec. VP Chief Legal Officer 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Richard Daniell officer: Exec. VP, European Commercial 5 BASEL STREET, PO BOX 3190, PETACH TIKVA L3 4951033
Richard D Francis officer: President and CEO IM LANGACHER 44, GREIFENSEE V8 8606
Hafrun Fridriksdottir officer: Executive VP, Global R&D 400 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Eli Shani officer: EVP,Global Marketing&Portfolio C/O TEVA, 5 BASEL STREET, P.O. BOX 3190, PETACH TIKVA L3 4951033
Tal Zvi Zaks director C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX